Earnings calls

Suven Life Scie. concall ledger

Every earnings call for SUVEN — management tone, guidance, KPIs and promise tracking, quarter by quarter.

SUVEN · 5 transcripts · Healthcare · latest Q3 FY20

Q3 FY20Published 14 Feb 2020Call held 14 Feb 2020

SUVEN Q3 FY20 Earnings Call Transcript & Analysis

SLS Book Value₹390 crSPL Book Value₹806 crSLS Cash₹150 crSPL Cash₹213 crSPL Working Capital Debt₹32 cr

SLS Book Value ₹390 cr; SPL Book Value ₹806 cr; SLS Cash ₹150 cr. Suven Life Sciences (SLS) SUVN-502 failed primary endpoint but secondary data promising for new indications, targeting new clinical trial.

Read full transcript & analysis

Q2 FY20Published 15 Nov 2019Call held 15 Nov 2019

SUVEN Q2 FY20 Earnings Call Transcript & Analysis

H1 FY20 Income Growth0.62 yoy+62% YoYH1 FY20 EBITDA Growth1.15 yoy+115% YoYH1 FY20 Net Profit Growth1.28 yoy+128% YoYQ2 FY20 Total CRAMS Revenue₹206 crQ2 FY20 Specialty Chemicals Revenue₹54 cr

H1 FY20 Income Growth 0.62 yoy (+62% YoY); H1 FY20 EBITDA Growth 1.15 yoy (+115% YoY); H1 FY20 Net Profit Growth 1.28 yoy (+128% YoY). H1 FY20 income increased by 62% YoY.

Read full transcript & analysis

Q1 FY20Published 16 Aug 2019Call held 16 Aug 2019

SUVEN Q1 FY20 Earnings Call Transcript & Analysis

Revenue Growth0.01 YoY+1% YoYEBITDA Growth0.4 YoY+40% YoYPAT Growth0.47 YoY+47% YoY

Revenue Growth 0.01 YoY (+1% YoY); EBITDA Growth 0.4 YoY (+40% YoY); PAT Growth 0.47 YoY (+47% YoY). Q1 FY20 Revenue remained flat YoY, with a potential 1% growth.

Read full transcript & analysis

Q4 FY19Published 27 May 2019Call held 27 May 2019

SUVEN Q4 FY19 Earnings Call Transcript & Analysis

Revenue₹645 cr+5% YoYEBITDA Margin36%

Revenue ₹645 cr (+5% YoY); EBITDA Margin (Suven Pharma) 36%. Q4 FY19 Revenue up 90% QoQ and PAT up 170% QoQ.

Read full transcript & analysis

Q3 FY19Published 06 Feb 2019Call held 06 Feb 2019

SUVEN Q3 FY19 Earnings Call Transcript & Analysis

Top-line Growth0%Bottom-line Growth-15%−15% YoYCommercial CRAMS Revenue₹38 crSUVN-502 R&D Spend4.85 million USDR&D Written Off₹42.4 cr

Top-line Growth 0.0%; Bottom-line Growth -15.0% (−15% YoY); Commercial CRAMS Revenue ₹38 cr. Q3 FY19 top-line was flat YoY, while bottom-line declined by 15% YoY.

Read full transcript & analysis